Drug intelligence / Profile preview

ABCIRT

Development stage: Preclinical
Lead developer: Agastiya Biotech
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules

Overview

ABCIRT is a small molecule radiopharmaceutical currently in preclinical development by Agastiya Biotech for the treatment of cancer. The therapeutic is designed to deliver radioisotopes specifically to cancerous tissues to induce localized cell death. As of early 2024, the specific molecular target, the radioisotope employed, and the precise mechanism of targeting remain proprietary and have not been publicly disclosed by the developer. It represents an expansion of Agastiya Biotech's oncology pipeline beyond its lead multi-targeted kinase inhibitor candidates.

Beyond the preview

Go deeper on ABCIRT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABCIRT.

Explore the full profile